✦ LIBER ✦

A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer

✍ Scribed by Jhaveri, Komal; Chandarlapaty, Sarat; Lake, Diana; Gilewski, Teresa; Robson, Mark; Goldfarb, Shari; Drullinsky, Pamela; Sugarman, Steven; Wasserheit-Leiblich, Carolyn; Fasano, Julie; Moynahan, Mary Ellen; D'Andrea, Gabriella; Lim, Kristina; Reddington, Laura; Haque, Sofia; Patil, Sujata; Bauman, Lynne; Vukovic, Vojo; El-Hariry, Iman; Hudis, Clifford; Modi, Shanu

Book ID: 121791729
Publisher: CIG Media Group, LP.
Year: 2014
Tongue: English
Weight: 438 KB
Volume: 14
Category: Article
ISSN: 1526-8209
DOI: 10.1016/j.clbc.2013.12.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II open-label study of sunitinib i

Phase II open-label study of sunitinib in patients with advanced breast cancer

✍ Denise A. Yardley, E. Claire Dees, Stephen D. Myers, Sherry Li, Paul Healey, Zhi 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 217 KB

Results of a phase II open-label, nonran

Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer

✍ John W. Smith; Kristi J. McIntyre; Patrick V. Acevedo; Carlos A. Encarnacion; Ka 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 230 KB

1230 POSTER A Phase 1 and Pharmacokineti

1230 POSTER A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, in Combination With Docetaxel in Subjects With Advanced Solid Tumour Malignancies

✍ R.D. Harvey; C.M. Lewis; J.S. Kauh; T.K. Owonikoko; A. Akintayo; M. Karol; F. Te 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

BP40 MULTICENTER PHASE II STUDY OF APATI

BP40 MULTICENTER PHASE II STUDY OF APATINIB, A NOVEL INHIBITOR OF VEGFR, IN HEAVILY PRETREATED PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER

✍ Hu, Xi-chun; Zhang, Jian; Xu, Bing-he; Jiang, Ze-fei; Tong, Zhong-sheng; Zhang, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Activity of IPI-504, a Novel Heat-Shock

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer

✍ Sequist, L. V.; Gettinger, S.; Senzer, N. N.; Martins, R. G.; Janne, P. A.; Lile 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 711 KB

Eribulin monotherapy versus treatment of

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

✍ Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 392 KB